incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
== Career == Reith graduated from University College London in 1962. She worked in London in the 1970s and then at the Southern General Hospital, Glasgow after she moved with her family to Scotland and became a specialist in the treatment of diabetes. She had moved to Stirling Royal Infirmary by January 1981.
The HisG domain of Cns3 converts adenosine into pentostatin. Cns4 is able to pump pentostatin out of the cell. One reasonable guess for its function would be that pumping out pentostatin allows cordycepin to be detoxified by deamination (cordycepin is toxic to the fungal cell in excessive concentrations). Intriguingly, the industrial fungus Acremonium chrysogenum features a gene cluster with high conservation with the Cns cluster, yet the fungus is not observed to produce cordycepin.
Here, the phosphorylated 5′ end of the RNA strand enters a conserved basic surface pocket and makes contacts through a divalent cation (an atom with two positive charges) such as magnesium and by aromatic stacking (a process that allows more than one atom to share an electron by passing it back and forth) between the 5′ nucleotide in the siRNA and a conserved tyrosine residue. This site is thought to form a nucleation site for the binding of the siRNA to its mRNA target. Analysis of the inhibitory effect of mismatches in either the 5' or 3' end of the guide strand has demonstrated that the 5' end of the guide strand is likely responsible for matching and binding the target mRNA, while the 3' end is responsible for physically arranging target mRNA into a cleavage-favorable RISC region. It is not understood how the activated RISC complex locates complementary mRNAs within the cell. Although the cleavage process has been proposed to be linked to translation, translation of the mRNA target is not essential for RNAi-mediated degradation. Indeed, RNAi may be more effective against mRNA targets that are not translated. Argonaute proteins are localized to specific regions in the cytoplasm called P-bodies (also cytoplasmic bodies or GW bodies), which are regions with high rates of mRNA decay; miRNA activity is also clustered in P-bodies. Disruption of P-bodies decreases the efficiency of RNAi, suggesting that they are a critical site in the RNAi process.
=== Parkinson's disease === α-Synuclein is a protein that is associated with Parkinson's disease. In humans, this protein is encoded by the SNCA gene. α-Synuclein is involved in recycling synaptic vesicles that carry neurotransmitters and naturally occurs in an unfolded form. Elevated levels of α-Synuclein are found in patients with Parkinson's disease. There is a correlation between the concentration of unphosphorylated α-Synuclein present in the patient and the severity of Parkinson's disease. Specifically, phosphorylation of Ser129 in α-Synuclein has an impact on severity. Healthy patients have higher levels of unphosphorylated α-Synuclein than patients with Parkinson's disease. The measurement of change in the ratio of concentrations of phosphorylated α-Synuclein to unphosphorylated α-Synuclein within a patient could be a marker of the disease progression. Antibodies that target α-Synuclein at phosphorylated Ser129 are used to study the molecular aspects of synucleinopathies. Phosphorylation of Ser129 is associated with the aggregation of the protein and further damage to the nervous system. The aggregation of phosphorylated α-Synuclein can be enhanced if a presynaptic scaffold protein, Sept4, is present in insufficient quantities. Direct interaction of α-Synuclein with Sept4 inhibits the phosphorylation of Ser129. However, phosphorylation of Ser129 can be observed without synuclein aggregation in conditions of overexpression.
On August 8, 2019, the Ford government severed the funding for court-ordered autism services for eight families with adult children with "severe" conditions who are at "serious risk of harm", who had been receiving the funding since 2004. Lawyers Scott Hutchison and Mary Eberts served notice of intent to sue in an 18-page letter to Social Services Minister Smith and Premier Ford "for breach of contract, negligence, and breach of Charter rights." It was formally filed in court on October 1. Those long-standing payments of about $1.7 million annually were the result of litigation against the previous provincial administrations, who had committed to continue the funding "until a co-ordinated transition to other services had been made, in a way that provided alternative services with which the families were satisfied", according to The Star. Faced with a backlash against "a botched revamp of autism services" in February 2019, the government had doubled the annual funding to $600 million for autism services but this did not restore the funding for these eight families.
Sources: en.wikipedia.org
The Honeywell Kitchen Computer was a special offering of the H316 pedestal model by Neiman Marcus in 1969 as one of a continuing series of extravagant gift ideas. It was offered for US$10,000 (equivalent to US$88,000 in 2025), weighed over 100 pounds (over 45 kg) and was advertised as useful for storing recipes. The imagined uses of the Honeywell Kitchen Computer also included assistance with meal planning and balancing the family checkbook – the marketing of which included highly traditional and patronizing representations of housewives. Reading or entering these recipes would have been nearly impossible for the average intended user, since the user interface required the user to complete a two-week course just to learn how to program the device, using only toggle-switch input and binary-light output. To round out the domestic marketing, the pedestal model's writing surface was rebranded as a built-in cutting board and the computer would have a few recipes built in. No evidence has been found that any Honeywell Kitchen Computers were ever sold, though Honeywell did sell a small number (less than 20) pedestal computers outside of the Neiman Marcus branding. Although a fantasy gift, the Kitchen Computer represented the first time a computer was offered as a consumer product.
== Deaths == In the United States, in 2003, a 17-year-old who, according to his parents, was self-treating his anxiety with home-brewed poppy seed tea, died of pulmonary edema caused by acute morphine and codeine intoxication. A Drug Alert posted by the DOJ in 2010 pointed to five deaths possibly resulting from drinking of poppy tea. Since 2010, not less than 10 deaths presumably related to poppy tea consumption were reported by the FDA's Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS). In Canada, on 19 May 2012, a 19-year-old from Nova Scotia died after drinking the tea from a poppy seed pod he purchased on the Internet. In November 2012, a Tasmanian youth died after drinking tea brewed from seed heads, and a 50-year-old Tasmanian man died in similar circumstances in February 2011. Some instances of death or injury associated with the consumption of poppy seed tea have involved users who combined the beverage with other nervous system depressants (i.e. alcohol, tranquillizers, benzodiazepines).
Natural killer cell (NK) therapies and CAR-NK cell approaches are also being explored, leveraging NK cells' innate ability to target tumor cells. Other strategies include cancer vaccines, which aim to provoke an immune response against tumor-associated antigens, and may be either preventive or therapeutic. Immunomodulatory agents such as cytokines (e.g., interleukin-2, interferon-alpha) and Bacillus Calmette-Guerin (BCG) are used to enhance immune activity or alter the tumor microenvironment. Oncolytic virus therapies, which employ engineered viruses to selectively kill cancer cells while promoting systemic immunity, are also under investigation. In 2018, American immunologist James P. Allison and Japanese immunologist Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation.
=== Preservation in a resin pour === A resin pour preservation allows for flowers like roses to be preserved in a clear transparent mould, making this method a great choice for ornamental preservation of flowers. Two separate resin elements are mixed in equal proportions and poured into a silicone mould, often in an ice cube shape, with the flower inserted. With each pour, a heat gun is used to remove air bubbles that form at the surface of the pour. Those attempting a resin pour preservation are recommended to wear a respirator and gloves as a resin pour can give off fumes and also a considerable amount of heat. The preservation of real dried flowers can also be done within a bezel-based structure poured with resin.
Sources: en.wikipedia.org
While the term embalming is used for both ancient and modern methods of preserving a deceased person, there is very little connection between the modern-day practices of embalming and ancient methods in terms of techniques or final aesthetic results. The Chinchorro culture in the Atacama desert of present-day Chile and Peru is among the earliest cultures known to have performed artificial mummification, as early as 5000–6000 BCE. The earliest known evidence of artificial preservation in Europe was found in Osorno (Spain) – approximately 5000-year-old human bones covered in cinnabar for preservation – however embalming remained unusual in Europe up to the time of the Roman Empire. Evidence of embalming practices in Egypt date to at least 3500 BCE. Ritual mummification, including embalming, continued to develop into a standardized practice in the dynastic period, and typically involved removing organs, ridding the body of moisture, and covering the body with natron, a mixture of desiccating salts found naturally in the Wadi El Natrun west of the Nile Delta. The ancient Egyptians believed that mummification enabled the soul to return to the preserved corpse after death. Other cultures known to have used embalming techniques in antiquity include the Meroites, Guanches, Peruvians, Jivaro Indians, Aztecs, Toltecs, Mayans, and Tibetan and southern Nigerian tribes. In China, artificially preserved remains have been recovered from the period of the Han dynasty (206 BCE–220 CE), the main examples being those of Xin Zhui and the Mawangdui Han tombs site.
==== Byzantine writers ==== Physician Oribasius (c. 320–403), personal physician of the emperor and philosopher Julian, compiled all known ancient medical texts of his time by theme into medical encyclopedia. He quotes Galen and Rufus on diabetes, considering it to be a polyuric disease of the kidneys. Various descriptive names are given for the condition, including: chamber-pot dropsy, diarrhea of the urine (diarrhea urinosa), and the thirsty disease. These descriptions, along with a number of other names for the condition ("liuria", "extreme thirst or dipsacus"), were echoed by later Byzantine writers in key encyclopedic texts.
Tholos de Montelirio is an archaeological site in Seville Province, Spain, at Valencina de la Concepción. It is a megalithic construction dated to 3,000–2,800 BC. The site was discovered in 1868, but has been abandoned for decades. Its excavation was resumed in 1980 due to the urban growth of Seville. Tholos de Montelirio is closed to the general public, but its objects can be viewed in the Archeological Museum of Seville.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.